Table 7.
Effect-size estimates for CPB stage in the validation cohort.
| Variables |
Case/
Total |
Survival
rate, % |
Unadjusted
HR (95% CI) |
Adjusted
HR (95% CI) |
|---|---|---|---|---|
| CPB stage | ||||
| Stage 1 | 10/80 | 81.02 | Reference | Reference |
| Stage 2 | 20/57 | 35.42 | 3.04 (1.42–6.49) | 3.15 (1.47–6.75) |
| Stage 3 | 17/57 | 64.07 | 2.73 (1.25–5.96) | 2.52 (1.13–5.62) |
Stage 1: CPB index ≤ 11; Stage 2: 11 < CPB index ≤ 17; Stage 3: CPB index > 17. Adjusted HR was adjusted for pirfenidone, nintedanib, steroids, and N-acetylcysteine. P was calculated by Kaplan–Meier analysis.